Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 5/2008

01-05-2008 | Original Article

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

Authors: Lidice Bernardo, Lisset Hermida, Jorge Martin, Mayling Alvarez, Irina Prado, Carlos López, Rafael Martínez, Rosmari Rodríguez-Roche, Aida Zulueta, Laura Lazo, Delfina Rosario, Gerardo Guillén, María G. Guzmán

Published in: Archives of Virology | Issue 5/2008

Login to get access

Abstract

The suitability of dengue 2 envelope domain III recombinant fusion proteins [(fusion (PD5) and insertion (PD3) variants)] for inducing functional antibodies and a protective immune response in nonhuman primates has been reported. However, the evaluation of the antibody response after immunization did not correlate with the protection data as measured by viremia detection. Here, we characterized the anamnestic immune response after viral challenge in monkeys immunized with the dengue 2 recombinant proteins in an attempt to define correlates of protection useful for vaccine studies. Monkeys immunized with PD5 (most protected group) exhibited an earlier increase in the anti-DENV-2 IgM response after challenge compared to control animals. Hemagglutination-inhibiting (HAI) antibodies were increased significantly earlier in PD5-immunized animals compared to those immunized with PD3. The fully protected monkeys showed the earliest HAI antibody response. These results underline the usefulness of the anamnestic antibody response for supporting protection data. The induction of an early HAI and IgM antibody response after challenge suggest a protective role against dengue virus (DENV) infection in monkeys, supporting their use as correlates of protection in vaccine studies.
Literature
1.
Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman MG (2005) Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 29:1–9
2.
Bray M, Men R, Lai CJ (1996) Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 70:4162–4166PubMed
3.
Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S (1991) Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 44:481–493PubMed
4.
Clarke DH, Casals J (1958) Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7:561–573PubMed
5.
Delenda C, Staropoli I, Frenkiel MP, Cabanie L, Deubel V (1994) Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75:1569–1578PubMed
6.
Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA (2005) rDEN4 Delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191:710–718PubMedCrossRef
7.
Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS (2006) The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2:167–173PubMed
8.
Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69:48–60PubMed
9.
Falconar AK (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144:2313–2330PubMedCrossRef
10.
Galler R, Marchevsky RS, Caride E, Almeida LF, Yamamura AM, Jabor AV, Motta MC, Bonaldo MC, Coutinho ES, Freire MS (2005) Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys. Braz J Med Biol Res 38:1835–1846PubMedCrossRef
11.
Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP (2001) Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75:7290–7304PubMedCrossRef
12.
Guzman MG, Mune M, Kouri G (2004) Dengue vaccine: priorities and progress. Expert Rev Anti Infect Ther 2:895–911PubMedCrossRef
13.
Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165–3171PubMedCrossRef
14.
Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179–3188PubMedCrossRef
15.
Laemmli UK (1970) Cleavage of structural protein during assembly of the head of bacteriophage T4. Nature 227:680–685PubMedCrossRef
16.
Markoff L, Pang X, Houng Hs HS, Falgout B, Olsen R, Jones E, Polo S (2002) Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 76:3318–3328PubMedCrossRef
17.
Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ (2000) Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18:3113–3122PubMedCrossRef
18.
Monath TP (1994) Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 91:2395–2400PubMedCrossRef
19.
Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22:250–254PubMed
20.
Pupo Antunez M, Rodriguez H, Vazquez S, Vilaseca JC, Alvarez M, Otero A, Guzman G (1997) Monoclonal antibodies raised to the dengue-2 virus (Cuban: A15 strain) which recognize viral structural proteins. Hybridoma 16:347–353PubMedCrossRef
21.
Putnak R, Feighny R, Burrous J, Cochran M, Hackett C, Smith G, Hoke C (1991) Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 45:159–167PubMed
22.
Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG (2000) Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81:1659–1667PubMed
23.
24.
Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, Chambonneau L, Deauvieau F, Lang J, Guy B (2006) Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24:4914–4926PubMedCrossRef
25.
Shi Y, Agematsu K, Ochs HD, Sugane K (2003) Funtional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol 108:128–137PubMedCrossRef
26.
Simantini E, Banerjee K (1995) Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies. Arch Virol 140:1257–1273PubMedCrossRef
27.
Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL (2003) Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69:24–31PubMed
28.
Towbin H, Staehelin T., Golden J (1979) Electrophoretic transfer of protein from polyacrylamide gel to nitrocellulose sheets procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354PubMedCrossRef
29.
Velzing J, Groen J, Drouet MT, van Amerongen G, Copra C, Osterhaus AD, Deubel V (1999) Induction of protective immunity against dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17:1312–1320PubMedCrossRef
30.
Zulueta A, Hermida L, Lazo L, Valdes I, Rodriguez R, Lopez C, Silva R, Rosario D, Martin J, Guzman MG, Guillen G (2003) The fusion site of envelope fragments from each serotype of dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 308:619–626PubMedCrossRef
Metadata
Title
Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins
Authors
Lidice Bernardo
Lisset Hermida
Jorge Martin
Mayling Alvarez
Irina Prado
Carlos López
Rafael Martínez
Rosmari Rodríguez-Roche
Aida Zulueta
Laura Lazo
Delfina Rosario
Gerardo Guillén
María G. Guzmán
Publication date
01-05-2008
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 5/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-008-0050-9

Other articles of this Issue 5/2008

Archives of Virology 5/2008 Go to the issue

Original Article

Recovery of viable porcine reproductive and respiratory syndrome virus from an infectious clone containing a partial deletion within the Nsp2-encoding region

Original Article

Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers

Original Article

Genetic variability of genome segments 3 and 9 of Fiji disease virus field isolates

Original Article

Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines

Brief Report

Polymorphism of the PRNP gene in the main breeds of indigenous Chinese goats

Original Article

Phylogeny and molecular genetic parameters of different stages of hepatitis B virus infection in patients from the Brazilian Amazon
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits